
Pioneering Endosurgery reflects Lumendi’s innovative, three-part pathway to:
expand indication areas and procedures in the upper gastrointestinal tract, which includes a recent submission to the FDA;
innovate improvements planned for the DiLumen EIP, including a proprietary lubricated inner surface of DiLumen’s sheath for better endoscope handling performance; and
commercially release the DiLumen C2 platform[1] to bring robotic-like end-effectors to endolumenal surgery in a low-cost, disposable format to provide endoscopists with unprecedented control of tissue.